©2004-2008, Quantum Laboratories, Inc.. All rights reserved.



Alzheimer's Dementia

• Protocol A2581078 A randomized, multi-center, parallel group, double blind study of the efficacy and safety of atorvastatin 80 mg plus an acethylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer’s disease.

• Protocol BI 1198.52 A Phase II Double Blind, Randomized, Dose Ranging, Placebo Controlled Multi-center, Safety and Efficacy Evaluation of three doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer’s Type.

For more information please call (561) 687-2111



Our facility identifies and recruits appropriate patients and monitors them during the study. If you qualify and consent to participate, there will be no charge for your study medication and office visits. Additionally, you are responsible for attendence to regular scheduled appointments.


During any one-year period, up to 50 million Americans suffer from clearly diagnosable mental disorder involving a degree of incapacity that interferes with employment, attendence at school or daily life.